UK co-ordinating investigator international clinical trial: Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

Activity: Internal positions, career professional development and otherOtherResearch

Held atBayer Pharma AG, Germany
Degree of RecognitionInternational


  • Copanlisib BAY80-6946
  • BAY 16349
  • Non-Hodgkin Lymphoma
  • Relapsed or refractory
  • PI3 kinase inhibitor

Research Beacons, Institutes and Platforms

  • Cancer